Brenntag, the global market leader in chemicals and ingredient distribution, has just announced an exclusive partnership with INOFEA to promote the pharmaceutical applications of its enzyme technology in EMEA.
As part of the exclusive partnership, Brenntag and INOFEA will provide support and services to enable customers to get the most out of INOFEA’s technology in their applications, such as protecting and enhancing the performance of their enzymes. Brenntag will leverage its global reach to promote INOFEA’s products and services within the pharmaceutical industry, including the manufacturers of APIs, biosimilars, intermediates, diagnostics and medical devices.
INOFEA has developed the enzzen® technology, enhancing enzyme stability, enabling recyclability and easy recovery in manufacturing steps. Enzymes earn a broader substrate range and achieve extraordinary reactivity by enhancing reaction rate and selectivity. Thus, customers need less raw materials for synthesis, less energy during the production process and can benefit from lower waste production and solvents used in biocatalytic processes.
“Working with INOFEA we are able to offer our pharmaceutical customers an innovative solution that can fulfil important sustainability requirements for future production processes,” comments Joakim Volke, President of Pharma EMEA. “Brenntag Specialties is excited to expand our service offerings with the enzzen®-enzymes, which is becoming part of our Green Alternatives Portfolio.”
Anne Timm, CEO of INOFEA: “We found an ideal partner in Brenntag to promote our technology to the pharma market in EMEA. As a company providing highly innovative solutions it is a big challenge to have our technology properly marketed and promoted within such a big and diversified market. We are sure Brenntag's huge and technically proficient resources will turn our potential into high-level opportunities, and this is only the first step of a very long-term and mutually profitable partnership.”
INOFEA, a biotech enterprise founded in Switzerland in 2014, is an enzyme-performance-improving company enabling sustainable manufacturing processes going hand in hand with a reduction of waste, pollution, and material consumption. INOFEA unfolds the potential of enzymes in biocatalysis and medical applications. The offerings include, among other activities, customized development of enzymes with superior properties focusing on the growing importance of defossilization in Life-Science industries. INOFEA enables the industry to make production of APIs economically and environmentally more sustainable, by reducing the number of intermediates versus chemical synthesis resulting in less waste, energy consumption and purification steps. The company has supply and licensing agreements in place and invests further into biocatalysis enabling customers reaching their ambitious sustainability goals.
Brenntag is the global market leader in chemicals and ingredients distribution. The company holds a central role in connecting customers and suppliers of the chemical industry. Headquartered in Essen, Germany, Brenntag has more than 17,000 employees worldwide and operates a network of about 700 sites in 78 countries. In 2021, Brenntag generated sales of around 14.4 billion EUR. The two global divisions, Brenntag Essentials and Brenntag Specialties, provide a full-line portfolio of industrial and specialty chemicals and ingredients as well as tailor-made application, marketing and supply chain solutions, technical and formulation support, comprehensive regulatory know-how, and digital solutions for a wide range of industries. In the field of sustainability, Brenntag pursues specific goals and is committed to sustainable solutions in its own sector and the industries served. Brenntag shares have been listed at the Frankfurt Stock Exchange since 2010, initially in the MDAX and since September 2021 in the DAX. In addition, the Brenntag SE shares are listed in the DAX 50 ESG and DAX ESG Target. For more information, visit www.brenntag.com